Aratana Therapeutics Inc. (PETX) Trading Up 4.5%
Aratana Therapeutics Inc. (NASDAQ:PETX)’s share price was up 4.5% during trading on Wednesday . The stock traded as high as $6.82 and last traded at $6.76, with a volume of 289,452 shares changing hands. The stock had previously closed at $6.47.
Several equities analysts have commented on PETX shares. Jefferies Group reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Aratana Therapeutics in a research report on Saturday, April 2nd. Credit Suisse Group AG reissued a “buy” rating on shares of Aratana Therapeutics in a research report on Saturday, April 2nd. William Blair reissued an “outperform” rating on shares of Aratana Therapeutics in a research report on Tuesday, April 26th. Zacks Investment Research raised Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $7.25 price target on the stock in a research report on Thursday, July 7th. Finally, Lake Street Capital reissued a “buy” rating and set a $15.00 price target on shares of Aratana Therapeutics in a research report on Sunday, July 17th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Aratana Therapeutics currently has an average rating of “Buy” and a consensus target price of $11.66.
The firm’s 50 day moving average price is $6.64 and its 200 day moving average price is $5.29. The company’s market cap is $232.23 million.
Aratana Therapeutics (NASDAQ:PETX) last issued its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by $0.10. The firm earned $0.17 million during the quarter, compared to analyst estimates of $0.13 million. During the same period last year, the business posted ($0.26) earnings per share. The company’s quarterly revenue was up 6.3% on a year-over-year basis. On average, analysts expect that Aratana Therapeutics Inc. will post ($1.02) EPS for the current year.
In related news, CEO Peter Steven St sold 100,000 shares of the company’s stock in a transaction that occurred on Friday, June 17th. The stock was sold at an average price of $6.26, for a total value of $626,000.00. Following the sale, the chief executive officer now owns 717,793 shares in the company, valued at approximately $4,493,384.18. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Julia A. Stephanus sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 28th. The stock was sold at an average price of $6.25, for a total value of $187,500.00. Following the completion of the sale, the insider now owns 127,503 shares in the company, valued at approximately $796,893.75. The disclosure for this sale can be found here.
An institutional investor recently raised its position in Aratana Therapeutics stock. Jennison Associates boosted its position in Aratana Therapeutics Inc. (NASDAQ:PETX) by 20.8% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,146,200 shares of the biopharmaceutical company’s stock after buying an additional 714,413 shares during the period. Jennison Associates owned approximately 11.84% of Aratana Therapeutics worth $35,077,000 as of its most recent filing with the SEC.
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company has licensed and is developing more than 18 therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target serious medical conditions, such as pain and inflammation, stimulation of appetite, cancer and other serious diseases for dogs and cats.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.